Literature DB >> 11896429

Respiratory syncytial virus infection following hematopoietic stem cell transplantation.

T N Small1, A Casson, S F Malak, F Boulad, T E Kiehn, J Stiles, H M Ushay, K A Sepkowitz.   

Abstract

Respiratory syncytial virus, one of the most common causes of respiratory infections in immunocompetent individuals, is frequently spread to recipients of HSCT by family members, other patients, and health care workers. In immunosuppressed individuals, progression from upper respiratory tract disease to pneumonia is common, and usually fatal if left untreated. We performed a retrospective analysis of RSV infections in recipients of autologous or allogeneic transplants. The incidence of RSV following allogeneic or autologous HSCT was 5.7% and 1.5%, respectively. Of the 58 patients with an RSV infection, 16 of 21 patients identified within the first post-transplant month, developed pneumonia. Seventy-two percent of patients received aerosolized ribavirin and/or RSV-IGIV, including 23 of 25 patients diagnosed with RSV pneumonia. In this aggressively treated patient population, three patients died of RSV disease, each following an unrelated HSCT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896429     DOI: 10.1038/sj.bmt.1703365

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  29 in total

Review 1.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

2.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

3.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.

Authors:  Rodrigo Martino; Rocío Parody Porras; Nuria Rabella; John V Williams; Elena Rámila; Nuria Margall; Rosa Labeaga; James E Crowe; Pedro Coll; Jorge Sierra
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

4.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

5.  Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation.

Authors:  Kari Neemann; Alison Freifeld
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 6.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

7.  Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.

Authors:  Teresa R Johnson; David Rangel; Barney S Graham; Douglas E Brough; Jason G Gall
Journal:  Mol Ther       Date:  2013-06-10       Impact factor: 11.454

8.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

9.  Reduction in incidence of non-COVID-19 respiratory virus infection amongst haematology inpatients following UK social distancing measures.

Authors:  Toby A Eyre; Louis Peters; Monique I Andersson; Andrew Peniket; David W Eyre
Journal:  Br J Haematol       Date:  2021-07-01       Impact factor: 8.615

Review 10.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.